SNOMED codes for Tirzepatide (Mounjaro®) Activity through the Obesity Pathway Innovation Programme
Pathway
These have also been listed in section 3.
| Terminology | SNOMED-CT |
|---|---|
| Referral to National Health Service Obesity Wraparound Support Pathway (procedure) | 2386201000000107 |
| Unsuitable for National Health Service Obesity Medication Pathway (Finding) | 2386221000000103 |
| Review of anti-obesity drug therapy (regime/therapy). | 2386251000000108 |
| National Health Service obesity medication pathway started (situation) | 2386231000000101 |
| National Health Service obesity medication pathway declined (situation) | 2386241000000105 |
| Anti-obesity drug therapy discontinued (situation) | 914821000000103 |
| National Health Service Obesity Medication Wraparound Support Pathway Not Completed (Situation) | 2612191000000103 |
Adverse drug reaction
| Terminology | SNOMED-CT |
|---|---|
| Adverse reaction to gastric inhibitory polypeptide (disorder) | 2385971000000102 |
| Adverse reaction to tirzepatide (disorder) | 2385981000000100 |
Additional Information
A key reporting challenge is that tirzepatide (Mounjaro®) is licensed for both type 2 diabetes and obesity and uses the same brand name for each indication. Prescribing activity must therefore be attributed accurately to the relevant indication so that OPIP reporting captures treatment for weight management only. The medication code for tirzepatide is SCTID: 41145911000001106. Sites should use the agreed pathway and activity codes alongside their local data to distinguish OPIP activity from prescribing for type 2 diabetes.
SNOMED consultation flow chart
Last edited: 9 November 2026 2:29 pm